Nectin Therapeutics Announces $5.4 Million Investment from Cancer Focus Fund to Support Phase 1 Study of First-in-Class Anti-PVR Targeted Immunotherapy

Written By Mukul Verma

First-in-Class Anti-PVR (CD155) Monoclonal Antibody NTX1088 Induces Anti-Tumor Immunity with Unique Triple Mechanism of Action Designed to Overcome Resistance to Approved Immune Checkpoint Inhibitors

Mukul Verma
Previous

Nectin Announces Extended Series A Financing to Over $25M and Start of Patient Dosing in Phase 1 Clinical Trial of First-in-Class Immunotherapy for Treatment of Patients with Advanced Solid Tumors
Next

KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers